

## vaccines - all results

| Treatment                       | Number of studies       | clinical deterioration  | clinical improvement | deaths  | viral clearance |
|---------------------------------|-------------------------|---|----------------------|---|-----------------|
| mRNA vaccine                    | 66 studies <sup>1</sup> | -   | -                    | 0.50 [0.11 ; 2.28], 2 RCTs, I2=0%<br>inconclusive result          | -               |
| Non replicating viral vector    | 34 studies <sup>2</sup> | -   | -                    | 0.19 [0.06 ; 0.64], 2 RCTs, I2=0%<br>moderate degree of certainty | -               |
| first booster dose              | 20 studies <sup>3</sup> | -   | -                    | 0.13 [0.08 ; 0.24], 6 studies, I2=78%<br>high degree of certainty | -               |
| Inactivated virus vaccine       | 12 studies <sup>4</sup> | -   | -                    | 0.20 [0.14 ; 0.28], 1 study, I2=0%<br>certainty unassessable      | -               |
| second booster dose             | 7 studies <sup>5</sup>  | -   | -                    | 0.22 [0.17 ; 0.28], 1 study, I2=0%<br>certainty unassessable      | -               |
| protein subunit vaccine         | 4 studies <sup>6</sup>  | -   | -                    | -   | -               |
| complete primary vaccine series | 1 study <sup>7</sup>    | 0.45 [0.34 ; 0.60], 3 studies, I2=66%<br>certainty unassessable | -                    | 0.16 [0.06 ; 0.41], 5 studies, I2=79%<br>high degree of certainty | -               |
| heterologous prime-boost        | 1 study <sup>8</sup>    | -   | -                    | -   | -               |

## Notes

<sup>1</sup>Haas, 2021 (emergency); BNT162b2 phase 3 (C4591001, Polack), 2020 (NCT04368728); COVE Moderna/NIH phase 3 (study 301), 2020 (NCT04470427); Moderna study 201 100µg, 2020 (NCT04405076); McConeghy, 2022 (); Nguyen, 2022 (); Amit, 2021 (); Dagan, 2021 (); SIREN (HW england), 2021 (ISRCTN11041050); Tang, 2021 (); Thompson, 2021 (); Agur, 0 (); Scotland cohort, 0 (); Shemer, 2021 (); Accorsi, 2022 (); Thompson -VISIO Network (omicron), 2022 (); Husby (Moderna), 2021 (); Husby (pfizer), 2021 (); Patone, 2021 (); Shasha, 2021 (); Abu-Raddad, 2022 (); Kirsebom (UKHSA), 2022 (); Angel, 2021 (); Barda, 2021 (); Bernal (PHE, 19th February 2021), 2021 (); Bjork, 2021 (); Burn (Pfizer), 2021 (); Chodcik, 2021 (); Edward (pfizer), 2021 (); EPI-PHARE, 2021 (); Goldberg, 2021 (); Haas, 2021 (); Heymann, 2021 (); Klein, 2021 (); Mayo Clinic (Puranik), 2021 (); McMurry, 2021 (); Moderna delta VOC press realease, 2021 (); Nanduri, 2021 (); Pawlowski, 2021 (); Shibli, 2021 (); Tartof, 2021 (NCT04848584); Weekes, 2021 (); Tande, 0 (); Lauring, 2022 (); Patalon, 2022 (); Southern California (Tseng) - delta, 2022 (); Southern California (Tseng) - omicron, 2022 (); Tenforde, 2022 (); Abu-Raddad, 2021 (); Chung, 2021 (); England (Andrews), 2021 (); Qatar (Tang), 2021 (); South Africa (Discovery Health, Collie), 2021 (); Tenforde, 2021 (); Wan, 2021 (); Aleman, 2021 (); Benotmane, 2021 (); Boyarsky, 2021 (); Palich, 2021 (); Rozen-Zvi, 2021 (); Yanay, 2021 (); Zadok, 2021 ()

<sup>2</sup>Asano, 2022 (NCT04568031); Com-COV2, 2022 (ISRCTN 27841311); Li J, 2022 (NCT04892459); AstraZeneca phase 3 US (D8110C00001), 2021 (NCT04516746); AstraZeneca phase 3 US (D8110C00001) 6 month follow up, 2021 (NCT04516746); Com-COV, 2021 (ISRCTN69254139); Fengcai, 2021 (NCT04566770); Kulkarni, 2021 (CTRI/2020/08/027170); Reindl-Schwaighofer, 2021 (); Sadoff, 2021 (NCT04436276);

AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)*safety*, 2020(); *CanSinophase2(Zhu)*, 2020(NCT04341389); *ChAdOx1phase3(AstraZeneca)*, 2020(NCT04400838); *RESIST(SputnikV Gam PHARE)*, 2022(); *EPIPHARE(Janssen)*, 2022(); *EPIPHARE(Vaxzevria)*, 2022(); *Hippisley-Cox*, 2021(); *Husby(Astra)*, 2021(); *Husby(janssen)*, 2021(); *Patone*, 2021(); *Simpson(ChAdOx1)*, 2021(); *Nabirova*<sup>3</sup>C4591031- first boost, 2021 (NCT04955626); Hall, 2021 (NCT04885907); Pfizer/BioNTech Booster study, 2021 (NCT04713553); COV13, 2022 (); McConeghy, 2022 (); Kislaya, 2022 (); Bar-On, 2021 (); Accorsi, 2022 (); Tan, 2022 (); Abu-Raddad, 2022 (); Arbel, 2021 (); Barda, 2021 (); Mattiuzzi, 2022 (); Ontario (Buchan), 2022 (); Patalon, 2022 (); Tenforde, 2022 (); England (Andrews), 2021 (); Patalon, 2021 (); Sisonke 2 (booster), 2021 (NCT05148845)

<sup>4</sup>PROFISCOV (SinoVac Brazil), 2021 (NCT04456595); Sinopharm Wuhan Vero cell, 2021 (NCT04510207); Xia (66), 2020 (ChiCTR2000032459); CoronaVac Indonesia, 0 (NCT04508075); Sinovac Turkish Trial, 0 (NCT04582344); Ashmawy, 2022 (); Faria, 2021 (); Chile study (Aaros ), 0 (); Hitchings, 2021 (); Li, 2021 (); Wan, 2021 (); Bonfa, 2021 (NCT04754698)

<sup>5</sup>Bar-On, 2022 (); Cohen, 2022 (); Arbel / Magen, 2022 (); Regev-Yochay (Comirnaty), 2022 (NCT05231005); Regev-Yochay (Spikevax), 2022 (NCT05231005)

<sup>6</sup>Novavax phase 2 South Africa (2019nCoV-501), 2021 (NCT04533399); Novavax phase 3 UK (2019nCoV-302), 2021 (NCT04583995); Novavax PREVEND-19 phase 3 US (2019nCoV-301), 2021 (NCT04611802); Keech, 2020 (NCT04368988)

<sup>7</sup>South Africa (Discovery Health, Collie), 2021 ()

<sup>8</sup>CombiVacS, 2021 (NCT04860739)